Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections
A. O'Donnell (Washington, DC, United States of America), J. Froehlich (Hayward, CA, United States of America), B. Thompson (Owings Mills, MD, United States of America), J. Dahms (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), I. Gonda (Hayward, CA, United States of America), C. Haworth (Cambridge, United Kingdom)
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Disease area: Respiratory infections
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. O'Donnell (Washington, DC, United States of America), J. Froehlich (Hayward, CA, United States of America), B. Thompson (Owings Mills, MD, United States of America), J. Dahms (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), I. Gonda (Hayward, CA, United States of America), C. Haworth (Cambridge, United Kingdom). Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections. 2682
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: